| Chaman Lal Sohal, MD | |
|
6742 Park Ave, Allen Park, MI 48101-2034 | |
| (313) 928-2333 | |
| Not Available |
| Full Name | Chaman Lal Sohal |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 46 Years |
| Location | 6742 Park Ave, Allen Park, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699758920 | NPI | - | NPPES |
| 1660060 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 4301044613 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henry Ford Wyandotte Hospital | Wyandotte, MI | Hospital |
| Beaumont Hospital - Dearborn | Dearborn, MI | Hospital |
| Harper University Hospital | Detroit, MI | Hospital |
| Beaumont Hospital - Trenton | Trenton, MI | Hospital |
| Beaumont Hospital - Wayne | Wayne, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apc Physicians Pllc | 7315260015 | 4 |
News Archive
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.
The future health of offspring is more negatively impacted when their mothers consume a high fat diet while nursing compared with high-fat diet consumption during pregnancy, according to animal research at Johns Hopkins University. These new research results are being presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior.
Bioscientists from the University of Kent have called for clinical trials to further investigate how traditional Chinese medicine (TCM) may have a positive effect on sperm genetic abnormalities, and thereby influence the success rate of male infertility treatment.
Making the most out of the Patient Protection and Affordable Care Act will also depend on something a little less exciting: putting the existing plan into action (Jonathan Cohn, 3/25).
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
› Verified 6 days ago
| Entity Name | St Mary Mercy Hospital Professional |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528145554 PECOS PAC ID: 2365521226 Enrollment ID: O20080502000426 |
News Archive
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.
The future health of offspring is more negatively impacted when their mothers consume a high fat diet while nursing compared with high-fat diet consumption during pregnancy, according to animal research at Johns Hopkins University. These new research results are being presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior.
Bioscientists from the University of Kent have called for clinical trials to further investigate how traditional Chinese medicine (TCM) may have a positive effect on sperm genetic abnormalities, and thereby influence the success rate of male infertility treatment.
Making the most out of the Patient Protection and Affordable Care Act will also depend on something a little less exciting: putting the existing plan into action (Jonathan Cohn, 3/25).
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
› Verified 6 days ago
| Entity Name | Ehk Endovascular Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477845824 PECOS PAC ID: 0648449272 Enrollment ID: O20110816000217 |
News Archive
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.
The future health of offspring is more negatively impacted when their mothers consume a high fat diet while nursing compared with high-fat diet consumption during pregnancy, according to animal research at Johns Hopkins University. These new research results are being presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior.
Bioscientists from the University of Kent have called for clinical trials to further investigate how traditional Chinese medicine (TCM) may have a positive effect on sperm genetic abnormalities, and thereby influence the success rate of male infertility treatment.
Making the most out of the Patient Protection and Affordable Care Act will also depend on something a little less exciting: putting the existing plan into action (Jonathan Cohn, 3/25).
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
› Verified 6 days ago
| Entity Name | Apc Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710383641 PECOS PAC ID: 7315260015 Enrollment ID: O20150105001816 |
News Archive
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.
The future health of offspring is more negatively impacted when their mothers consume a high fat diet while nursing compared with high-fat diet consumption during pregnancy, according to animal research at Johns Hopkins University. These new research results are being presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior.
Bioscientists from the University of Kent have called for clinical trials to further investigate how traditional Chinese medicine (TCM) may have a positive effect on sperm genetic abnormalities, and thereby influence the success rate of male infertility treatment.
Making the most out of the Patient Protection and Affordable Care Act will also depend on something a little less exciting: putting the existing plan into action (Jonathan Cohn, 3/25).
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
› Verified 6 days ago
| Entity Name | Downriver Vascular Associates Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386108835 PECOS PAC ID: 7113267824 Enrollment ID: O20190315001363 |
News Archive
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.
The future health of offspring is more negatively impacted when their mothers consume a high fat diet while nursing compared with high-fat diet consumption during pregnancy, according to animal research at Johns Hopkins University. These new research results are being presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior.
Bioscientists from the University of Kent have called for clinical trials to further investigate how traditional Chinese medicine (TCM) may have a positive effect on sperm genetic abnormalities, and thereby influence the success rate of male infertility treatment.
Making the most out of the Patient Protection and Affordable Care Act will also depend on something a little less exciting: putting the existing plan into action (Jonathan Cohn, 3/25).
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chaman Lal Sohal, MD 6742 Park Ave, Allen Park, MI 48101-2034 Ph: (313) 928-2333 | Chaman Lal Sohal, MD 6742 Park Ave, Allen Park, MI 48101-2034 Ph: (313) 928-2333 |
News Archive
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.
The future health of offspring is more negatively impacted when their mothers consume a high fat diet while nursing compared with high-fat diet consumption during pregnancy, according to animal research at Johns Hopkins University. These new research results are being presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior.
Bioscientists from the University of Kent have called for clinical trials to further investigate how traditional Chinese medicine (TCM) may have a positive effect on sperm genetic abnormalities, and thereby influence the success rate of male infertility treatment.
Making the most out of the Patient Protection and Affordable Care Act will also depend on something a little less exciting: putting the existing plan into action (Jonathan Cohn, 3/25).
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
› Verified 6 days ago
Dr. Jeffrey Michael Gutman, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 16407 Southfield Rd, Allen Park, MI 48101 Phone: 313-271-3000 Fax: 313-271-3003 | |
Cheng Chong Lee, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6742 Park Ave, Allen Park, MI 48101 Phone: 313-928-2333 | |
Vinod Bihari Sanghi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6540 Park Ave, Allen Park, MI 48101 Phone: 313-381-2528 Fax: 313-381-3002 | |
Subrahmanya Sarma Yellayi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6742 Park Ave, Allen Park, MI 48101 Phone: 313-928-2333 | |
Dr. Tareq Baghal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6742 Park Ave, Allen Park, MI 48101 Phone: 313-928-2333 | |
Anand N Hiremath, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 16407 Southfield Rd Ste 207, Allen Park, MI 48101 Phone: 313-271-3000 Fax: 313-271-3003 | |
Mohammed Yazbek, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 15101 Southfield Rd, Suite 101, Allen Park, MI 48101 Phone: 313-383-3333 Fax: 313-383-5555 |